Inositec
is a Switzerland-based biopharmaceutical company that develops and markets small molecule therapeutics to treat soft tissue and vascular calcification disorders... Read moreInositec
is a Switzerland-based biopharmaceutical company that develops and markets small molecule therapeutics to treat soft tissue and vascular calcification disorders... Read more
News
Nov 26, 2021
FinSMEs
Inositec: Vifor Pharma Acquires Inositec
Nov 22, 2021
Benzinga
Inositec: Vifor Pharma Bolsters Its Presence In Vascular Calcification Field Via Two Acquisition Deals
Nov 22, 2021
startupticker
Inositec: Vifor Pharma to acquire Inositec
Nov 22, 2021
MedCity News
Inositec: Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions
Oct 07, 2020
MarketScreener
Inositec: Inositec : Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors
May 04, 2020
MarketScreener
Inositec: Inositec : Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001
May 04, 2020
Pharmabiz
Inositec: Inositec receives US patent covering its platform of inositol phosphate analogs and specifically INS3001
Feb 05, 2020
BioPortfolio
Inositec: Inositecs INS3001 Significantly Reduces Cardiovascular Calcification in ProofofConcept Studies Published in Nature Communications
Oct 30, 2018
startupticker
Inositec: Inositec to launch clinical studies for its drug against kidney-related issues
Oct 26, 2018
PharmiWeb
Inositec: Inositec's INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates
Inositec Competitors
1
2
3
4
5
6
7
8
9
10